Slow Stepwise Propofol TCI Induction for Titration Anesthesia Maintenance

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-08-31

Study Completion Date

2021-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if a slow stepwise propofol TCI induction with Marsh model (Ke0 0.26), allows for an accurate estimation of the effect site concentration required for maintenance of the general anesthesia, with propofol and remifentanil, in adult populations older and younger than 65 years of age.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Different Propofol Formulations With or Without Remifentanil

NCT01592162

Anesthesia

COMPLETED PHASE4

Hemodynamics During Induction of General Anesthesia With High and Low Propofol Dose.

NCT03861364

Hemodynamics Instability Anesthesia, General Anesthesia, Intravenous

COMPLETED PHASE4

Evaluation of a Novel Closed-loop Propofol and Remifentanil System Guided by Bispectral Index Compared to a TCI Open-loop System

NCT02492282

Anesthesia, General Anesthesia, Intravenous

COMPLETED PHASE3

THe Comparison of Target Controlled Infusion of Propofol or Etomidate at General Anesthesia in Geriatric Patients

NCT02111265

Adrenal Suppression Hemodynamic Instability

UNKNOWN PHASE4

Target-controlled Infusion of Propofol and Remifentanil for Postoperative Sedation Guided by the Bispectral Index

NCT00393003

Postoperative Sedation

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Introduction: Currently, propofol is the most widely used intravenous anesthetic drug that is able to provide a safe general anesthesia. Propofol can be administered by using different techniques including target controlled infusion (TCI). The ability to maintain the pharmacological conditions after achieving a predetermined clinical effect is one of the major advantages of this technique. Although the use of TCI devices has increased in common clinical practice, whether or not all patients are suitable for TCI remains unclear. Pharmacological models were created based on information from healthy volunteers which may not apply for specific clinical conditions resulting either in over- or sub-dosed when using certain drugs.

It is not only individual variability in the pharmacokinetic (PK) parameters of the anesthetic that is a clinical problem, but it is also the pharmacodynamic variability. A previous study showed up to 6 times the inter-individual difference among young volunteers in loss of consciousness (LOC) and return of consciousness (ROC). In addition, greater differences may be found in the elderly.

Inaccurate general models require the anesthetic team to manually tailor medication requirements for each individual based on the desired therapeutic effect.

The purpose of this study is to evaluate if a slow stepwise propofol TCI induction with Marsh model (Ke0 0.26), assessed by clinical and electroencephalographic parameters, allows for an accurate estimation of the effect concentration required for hypnosis titration and maintenance of the general anesthesia, in adult populations older and younger than 65 years of age.

General Objective

• To establish whether a guided slow stepwise guided propofol induction with TCI represents a good correlation between the calculated Effect-Site Concentration (Ce) for the loss of consciousness and the required Ce to maintain a bispectral index (BIS) value between 45 and 65 during anesthesia maintenance in both age populations

Specific Objectives

* To determine the BIS value achieved with every propofol infusion based on the calculated Ce for the time of loss of consciousness (TLOC)
* To compare the drug infused per time unit required for the loss of consciousness in both groups
* To compare the time and Ce required to achieve loss of consciousness in both groups
* To evaluate the impact of remifentanil during hypnosis by using the BIS index

Hypothesis

During a slow stepwise anesthetic induction with TCI using the Marsh Model 4.0, the calculated Ce for the TLOC is comparable to the Ce required for the maintenance of the hypnosis during the general anesthesia, overcoming the inter-individual variability.

Methods

Experimental study, prospective clinical trial, phase 4. Each subject will be assigned to the propofol induction modality as described in the "intervention" section.

Once consciousness has been lost and maintenance target concentration has been established, manual ventilation will be initiated. Remifentanil TCI 6 ng/ml and a neuromuscular relaxant will be administered afterwards in order to perform endotracheal intubation. An infusion of phenylephrine between 0,1 and 0,4 mcg/kg/min will be initiated in order to maintain blood pressure values within 20% of the baseline value.

Continuous monitoring of BIS will be maintained after remifentanil infusion and intubation. Three minutes after endotracheal intubation, surgery will be prepared following standard procedures. BIS, spectrogram, and hemodynamics will be registered every 15 seconds, continuously, and every 3 minutes during 10 minutes respectively.

Subsequently, propofol Ce at TLOC will be established (if any modifications were necessary after TLOC) and it will be observed for another 30 minutes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Target Controlled Infusion Induction of Anesthesia Bispectral Index

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1

Patients \< 65 years old Propofol 1% TCI induction using plasma concentration, Marsh model (Ke0=0.26 min-1) at 1 mcg/ml, increasing the target concentration by 0.5 mcg/ml every minute until LOC. Remifentanil TCI 6 ng/ml and a neuromuscular relaxant will be administered afterwards in order to perform endotracheal intubation. CeLOC propofol concentration will be established and it will be observed for another 30 minutes. If BIS \<40 or \>65 propofol target concentration will be modified by 0,3 mcg/ml.

Group Type EXPERIMENTAL

Propofol

Intervention Type DRUG

Propofol intravenously by a stepwise TCI titration with Marsh pharmacokinetic model

Remifentanil Hydrochloride

Intervention Type DRUG

Remifentanil intravenously 6 ng/ml by TCI effect site, 3 min prior to intubation and maintained at that concentration throughout the study. If clinical signs of inadequate analgesia are present, remifentanil target concentration will be increased by 1 ng/ml.

Group 2

Patients ≥ 65 years old Propofol 1% TCI induction using plasma concentration, Marsh model (Ke0=0.26 min-1) at 1 mcg/ml, increasing the target concentration by 0.5 mcg/ml every minute until LOC. Remifentanil TCI 6 ng/ml and a neuromuscular relaxant will be administered afterwards in order to perform endotracheal intubation. CeLOC propofol concentration will be established and it will be observed for another 30 minutes. If BIS \<40 or \>65 propofol target concentration will be modified by 0,3 mcg/ml.

Group Type EXPERIMENTAL

Propofol

Intervention Type DRUG

Propofol intravenously by a stepwise TCI titration with Marsh pharmacokinetic model

Remifentanil Hydrochloride

Intervention Type DRUG

Remifentanil intravenously 6 ng/ml by TCI effect site, 3 min prior to intubation and maintained at that concentration throughout the study. If clinical signs of inadequate analgesia are present, remifentanil target concentration will be increased by 1 ng/ml.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Propofol

Propofol intravenously by a stepwise TCI titration with Marsh pharmacokinetic model

Intervention Type DRUG

Remifentanil Hydrochloride

Remifentanil intravenously 6 ng/ml by TCI effect site, 3 min prior to intubation and maintained at that concentration throughout the study. If clinical signs of inadequate analgesia are present, remifentanil target concentration will be increased by 1 ng/ml.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fresofol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ASA 1 or 2.
* Age over 20 years old.
* Scheduled to undergo elective surgery of minor or medium complexity under general anesthesia.
* Regarding cognitive function: subjects will be considered with enough cognitive function if they are able to read and understand the medical history form by properly answering medical questions during the preoperative anesthesia assessment and being also able to sign the informed consent form.

Exclusion Criteria

* Pregnancy.
* Obesity (BMI \>30).
* Patients taking benzodiazepines or other central nervous system action drugs.
* Subjects with psychiatric disorders with or without treatment.
* Allergies or any adverse reaction to propofol or any of its components (egg lecithin).

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No